Ticker Details
4D Molecular Therapeutics, Inc.
IPO Date:	December 11, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$451.67M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.64 | 3.89%
Avg Daily Range (30 D):	$0.39 | 4.12%
Avg Daily Range (90 D):	$0.31 | 3.28%

Institutional Daily Volume
Avg Daily Volume:	.46M
Avg Daily Volume (30 D):	.63M
Avg Daily Volume (90 D):	.64M

Trade Size
Avg Trade Size (Sh.):	76
Avg Trade Size (Sh.) (30 D):	68
Avg Trade Size (Sh.) (90 D):	70

Institutional Trades
Total Institutional Trades:	1,225
Avg Institutional Trade:	$1.78M
Avg Institutional Trade (30 D):	$1.68M
Avg Institutional Trade (90 D):	$1.35M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.71M
Avg Closing Trade (30 D):	$.94M
Avg Closing Trade (90 D):	$1M
Avg Closing Volume:	105.07K

News

Feb 19, 2026 @ 1:00 PM 4DMT to Participate in Upcoming Investor Conferenc... Source: Na

Nov 17, 2025 @ 11:00 AM 4DMT Appoints Kristian Humer as Chief Financial Of... Source: 4D Molecular Therapeutics

Oct 31, 2025 @ 3:02 AM 4DMT Announces Exclusive License Agreement with Ot... Source: 4D Molecular Therapeutics

Sep 11, 2025 @ 10:00 AM GenVivo Strengthens Oncology Leadership with Appoi... Source: Genvivo, Inc.

Aug 11, 2025 @ 12:16 PM 4dMT Revenue Jumps 200 Percent in Q2 Source: Jesterai

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-2.57	$-1.01	$.43
Diluted EPS	$-2.57	$-1.01	$.43
Revenue	$88.24M	$3.05M	$85.09M
Gross Profit
Net Income / Loss	$-160.9M	$-68.76M	$19.4M
Operating Income / Loss	$-179.55M	$-73.62M	$14.72M
Cost of Revenue
Net Cash Flow	$-76.85M	$12.25M	$11.69M
PE Ratio